In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CoreValve May Go From “Superior” To Stalled Following Court Ruling

This article was originally published in The Gray Sheet

Executive Summary

[Updated to incorporate comments from Edwards and Medtronic about ongoing negotiations, and more details on Medtronic’s emergency motion] A preliminary injunction ruling for Medtronic’s CoreValve device is an unexpected twist in a long-running transcatheter aortic valve patent suit between Medtronic and Edwards Lifesciences, and could give Edwards a significant edge in the market for several years to come.

You may also be interested in...

Medtronic Nabs First Superiority Outcome In TAVR Versus Surgery

Data from Medtronic’s CoreValve High Risk Study provide the firm with significant momentum toward expanding the FDA label for its transcatheter aortic valve replacement device. Based on the results, FDA says no advisory panel will need to meet for the firm’s high-risk surgery submission. Observers say the jury is still out on CoreValve versus Sapien question.

Edwards Wins Latest Round In TAVI Patent Dispute With Medtronic

A jury in Delaware awarded Edwards $393.6 million in damages plus royalties after determining Medtronic’s CoreValve infringes Edwards’ Cribier patent. While Medtronic might be paying royalties to Edwards for the next several years, Medtronic also got some very positive news last week: FDA approved CoreValve for patients too sick for surgery months earlier than expected.

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts